Evvy, a leader in at-home vaginal microbiome testing, announced a $40 million Series B funding round led by Catalio Capital Management. The company aims to deepen research on female health through a growing dataset and AI-powered insights.
- Raised $40M Series B led by Catalio Capital Management
- Over 100,000 patients served with at-home vaginal microbiome testing
- Expanding research into fertility and women's health biomarkers using AI
What happened
Evvy announced a $40 million Series B funding round led by Catalio Capital Management. Founded in 2021, Evvy has developed the only at-home vaginal microbiome test certified by CLIA and CLEP, which allows users to mail in swab samples for deep microbial analysis using metagenomic sequencing.
The company has grown to serve over 100,000 patients and collaborates with 3,000 healthcare practitioners. Its platform provides personalized clinical interpretations, diagnoses, and treatment pathways based on microbiome data. Recently, Evvy also launched an AI assistant to help users understand their vaginal health data and guide clinical interactions.
Why it matters
Evvy addresses a significant gap in precision medicine by generating high-quality, female-specific biological data that has traditionally been lacking. This data is essential to develop effective AI-driven models tailored to women's health, a field where existing datasets and medical AI often underperform due to a lack of representative inputs.
By linking vaginal microbiomes with health outcomes such as bacterial vaginosis subtypes, fertility success, and gynecological conditions, Evvy aims to build a continuous feedback loop that improves diagnostics, treatments, and biomarker discovery. This approach has the potential to reduce unexplained infertility and other unresolved female health issues.
What to watch next
Evvy is expanding into fertility research by studying connections between vaginal microbiomes and conditions like IVF success, preterm birth, and recurrent pregnancy loss. The company has initiated prospective studies in IVF clinics, aiming to translate microbiome insights into reproductive health interventions.
Long-term, Evvy plans to develop a new generation of non-invasive, at-home tests akin to a modern Pap smear. This would enable ongoing monitoring of infections, inflammation, fertility issues, and hormone-related conditions, empowering women to actively contribute data that drives advances in healthcare.